With €16.8 Billion in Cash and a Pipeline to Prove, BioNTech Faces ASCO's Verdict
Published on 05/23/2026 at 14:13 | Redaktion boerse-global.de
BioNTech’s stock closed Friday at €79.50, roughly 22% below its 52-week high and barely a tenth above the cycle low of €72.50. The divergence could not be starker: while the Mainz-based biotech is barrelling into the American Society of Clinical Oncology (ASCO) annual meeting in Chicago with a deep oncology pipeline, the market has punished the shares by more than 15% over the past month. The 200-day moving average of €86.47 sits untouched above current levels, and the relative strength index at 50.6 points to a market that has yet to pick a directional bet.
That disconnect is not lost on sell-side analysts. Bernstein initiated coverage with a Market Perform rating and a $96 price target, acknowledging BioNTech’s fortress balance sheet — roughly €16.8 billion in cash at the end of the first quarter — while flagging elevated pipeline approval risk. J.P. Morgan shortly before reaffirmed its Hold rating. Yet the broader consensus from 17 analysts stands at Buy, with an average target of $125.45, implying a 38% upside from Friday’s close.
The catalysts that could close that gap will be on full display from May 29 to June 2 in Chicago. Two oral presentations will feature BioNTech’s key oncology candidates: Pumitamig and Gotistobart. These are not early-stage experiments; both are generating what the company describes as consistent positive signals across multiple tumor types.
Should investors sell immediately? Or is it worth buying BioNTech?
Pumitamig, a bispecific immunomodulator that combines PD-L1 inhibition with VEGF-A neutralization, has already produced encouraging data in small-cell lung cancer and triple-negative breast cancer. The third dataset comes from the phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer, where it is being tested alongside chemotherapy. A head-to-head phase 3 study against the standard pembrolizumab-plus-chemo regimen is already running.
Gotistobart, a CTLA-4 antibody designed to selectively deplete regulatory T-cells, is being evaluated in the phase 2 PRESERVE-004 trial for platinum-resistant ovarian cancer. Here it is combined with pembrolizumab in a chemotherapy-free regimen that aligns with BioNTech’s long-term ambition to eliminate chemo from treatment protocols. Earlier data in lung cancer tested Gotistobart as a monotherapy; the combination approach is the new strategic focus.
The financial muscle to sustain this pipeline is considerable. BioNTech’s research spending hit €557 million in the first quarter alone, and the company is running more than 25 phase 2 and phase 3 studies, including 13 that are potentially pivotal. This year it plans to launch an additional six phase 3 trials, bringing the total to 15, and expects to release seven late-stage data packages by year-end. The 2026 revenue forecast stands at $2.3 billion to $2.6 billion, a target the company recently reaffirmed.
For now, the market is looking for proof that the oncology franchise can fill the void left by shrinking Covid vaccine sales. The ASCO presentations — two of the most closely watched data reads in BioNTech’s recent history — are the next tangible test. If Pumitamig and Gotistobart deliver, the 38% gap between the current price and the analyst consensus may begin to close.
Ad
BioNTech Stock: New Analysis - 23 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
